A panel of federal health advisers voted Wednesday to recommend approval for an experimental drug to treat Lou Gehrig s disease, a remarkable turnaround for the much-debated medication that was previously rejected by the same group earlier this year.
The Food and Drug Administration advisers voted 7-2 that data from Amylyx Pharma warranted approval, despite ongoing concerns about the strength and reliability of the company’s study. The vote is not binding a